Table 2 Baseline values for outcome variables for diabetes, hypertension and dyslipidemia guidelines in the control and intervention groups
Control group (% of patients) | Intervention group (% of patients) | |
|---|---|---|
Diabetes guideline | ||
Annual HbA1c testing | 77.05 | 76.18 |
HbA1c < 7% | 44.53 | 44.94 |
Annual general laboratory testing | 42.13 | 38.18 |
Annual coronary risk assessment | 10.48 | 10.88 |
Annual foot examination | 44.87 | 40.12 |
Blood pressure < 140/80 mmHg | 21.22 | 21.47 |
Metformin/All new antidiabetic monotherapy | 85.61 | 85.55 |
Hypertension guideline | ||
Annual basic lab examination | 24.46 | 21.81 |
Blood pressure < 140/90 mmHg | 29.98 | 31.47 |
Annual coronary risk assessment | 10.77 | 11.46 |
Diuretics/All new antihypertensive monotherapy | 11.41 | 10.57 |
Beta blockers/All new antihypertensive monotherapy | 6.85 | 7.77 |
ARB-II/All new antihypertensive monotherapy | 28.75 | 26.23 |
Dyslipidemia guideline | ||
Women with coronary risk assessment | 7.73 | 7.48 |
Men with coronary risk assessment | 7.70 | 7.06 |
New statin treatments with previous coronary risk assessment | 10.60 | 10.17 |
New statin treatments in low-risk women | 3.21 | 3.25 |
Patients with coronary heart disease receiving statin treatment | 76.54 | 73.56 |